Die Empfehlungen der Europäischen Lebergesellschaft (EASL) zur Behandlung der Hepatitis C (Version 2018) View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-08

AUTHORS

Markus Peck-Radosavljevic

ABSTRACT

The European Association for the Study of the Liver (EASL) has presented updated recommendations for the treatment of acute and chronic hepatitis C. From this, the recommendations relevant for Austrian and European practice have been extracted, taking into account current developments in the diagnostic workup including the necessary screening measures, treatment indications and therapeutic measures to be initiated as well as the contraindications to be observed. The use of various fixed combinations for different genotypes depending on liver pathology is comprehensively presented. The specific situations of substance abuse or relevant concomitant medication, after liver transplantation, in the case of hepatitis C virus (HCV) recurrent disease and in the presence of immune complex deposits are also discussed. In the case of HCV-positive organ recipients and donors and in the case of renal insufficiency or other relevant comorbidities, anti-HCV therapy must be adapted accordingly. Separate monitoring of therapy might be necessary. Treatment of children and adolescents should be tailored to the specific needs of the age group concerned. However, pangenotypical regimes have not yet been approved for children under 12 years of age. The indication of the various effective substances in primary therapy and after possible therapy failure must be made individually and take into consideration the individual disease constellations. Where appropriate, resistance testing can be of help. After successful treatment, individually adapted aftercare should be provided in order to recognize possible progression of liver disease or reinfections at an early stage. More... »

PAGES

87-96

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s41971-018-0034-x

DOI

http://dx.doi.org/10.1007/s41971-018-0034-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1106967551


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Abteilung Gastroenterologie und Hepatologie, Endokrinologie, Rheumatologie und Nephrologie, Klinikum Klagenfurt am W\u00f6rthersee, Feschnigstra\u00dfe\u00a011, 9020, Klagenfurt, \u00d6sterreich", 
          "id": "http://www.grid.ac/institutes/grid.415431.6", 
          "name": [
            "Abteilung Gastroenterologie und Hepatologie, Endokrinologie, Rheumatologie und Nephrologie, Klinikum Klagenfurt am W\u00f6rthersee, Feschnigstra\u00dfe\u00a011, 9020, Klagenfurt, \u00d6sterreich"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peck-Radosavljevic", 
        "givenName": "Markus", 
        "id": "sg:person.01046032607.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046032607.37"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2018-08", 
    "datePublishedReg": "2018-08-01", 
    "description": "The European Association for the Study of the Liver (EASL) has presented updated recommendations for the treatment of acute and chronic hepatitis C. From this, the recommendations relevant for Austrian and European practice have been extracted, taking into account current developments in the diagnostic workup including the necessary screening measures, treatment indications and therapeutic measures to be initiated as well as the contraindications to be observed. The use of various fixed combinations for different genotypes depending on liver pathology is comprehensively presented. The specific situations of substance abuse or relevant concomitant medication, after liver transplantation, in the case of hepatitis C virus (HCV) recurrent disease and in the presence of immune complex deposits are also discussed. In the case of HCV-positive organ recipients and donors and in the case of renal insufficiency or other relevant comorbidities, anti-HCV therapy must be adapted accordingly. Separate monitoring of therapy might be necessary. Treatment of children and adolescents should be tailored to the specific needs of the age group concerned. However, pangenotypical regimes have not yet been approved for children under 12 years of age. The indication of the various effective substances in primary therapy and after possible therapy failure must be made individually and take into consideration the individual disease constellations. Where appropriate, resistance testing can be of help. After successful treatment, individually adapted aftercare should be provided in order to recognize possible progression of liver disease or reinfections at an early stage.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s41971-018-0034-x", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1035274", 
        "issn": [
          "1728-6263", 
          "1728-6271"
        ], 
        "name": "Journal f\u00fcr Gastroenterologische und Hepatologische Erkrankungen", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "16"
      }
    ], 
    "keywords": [
      "anti-HCV therapy", 
      "chronic hepatitis C.", 
      "immune complex deposits", 
      "treatment of children", 
      "years of age", 
      "disease constellation", 
      "primary therapy", 
      "hepatitis C.", 
      "concomitant medications", 
      "liver transplantation", 
      "recurrent disease", 
      "renal insufficiency", 
      "relevant comorbidities", 
      "hepatitis C", 
      "organ recipients", 
      "therapy failure", 
      "treatment indications", 
      "liver disease", 
      "diagnostic workup", 
      "successful treatment", 
      "therapeutic measures", 
      "liver pathology", 
      "possible progression", 
      "age groups", 
      "resistance testing", 
      "substance abuse", 
      "European Association", 
      "therapy", 
      "screening measure", 
      "complex deposits", 
      "treatment", 
      "effective substances", 
      "disease", 
      "children", 
      "indications", 
      "early stages", 
      "comorbidities", 
      "contraindications", 
      "medications", 
      "different genotypes", 
      "transplantation", 
      "reinfection", 
      "insufficiency", 
      "workup", 
      "aftercare", 
      "pathology", 
      "recipients", 
      "cases", 
      "liver", 
      "progression", 
      "recommendations", 
      "age", 
      "Behandlung", 
      "adolescents", 
      "association", 
      "measures", 
      "specific needs", 
      "abuse", 
      "failure", 
      "group", 
      "years", 
      "donors", 
      "genotypes", 
      "testing", 
      "study", 
      "substances", 
      "specific situations", 
      "C.", 
      "presence", 
      "monitoring", 
      "European practice", 
      "use", 
      "need", 
      "practice", 
      "separate monitoring", 
      "stage", 
      "combination", 
      "development", 
      "constellation", 
      "current developments", 
      "consideration", 
      "help", 
      "situation", 
      "deposits", 
      "order", 
      "regime", 
      "account current developments", 
      "necessary screening measures", 
      "relevant concomitant medication", 
      "hepatitis C virus (HCV) recurrent disease", 
      "C virus (HCV) recurrent disease", 
      "virus (HCV) recurrent disease", 
      "HCV-positive organ recipients", 
      "pangenotypical regimes", 
      "possible therapy failure", 
      "individual disease constellations", 
      "Empfehlungen der Europ\u00e4ischen Lebergesellschaft (EASL) zur Behandlung", 
      "der Europ\u00e4ischen Lebergesellschaft (EASL) zur Behandlung", 
      "Europ\u00e4ischen Lebergesellschaft (EASL) zur Behandlung", 
      "Lebergesellschaft (EASL) zur Behandlung", 
      "zur Behandlung"
    ], 
    "name": "Die Empfehlungen der Europ\u00e4ischen Lebergesellschaft (EASL) zur Behandlung der Hepatitis C (Version 2018)", 
    "pagination": "87-96", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1106967551"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s41971-018-0034-x"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s41971-018-0034-x", 
      "https://app.dimensions.ai/details/publication/pub.1106967551"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:31", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_763.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s41971-018-0034-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s41971-018-0034-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s41971-018-0034-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s41971-018-0034-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s41971-018-0034-x'


 

This table displays all metadata directly associated to this object as RDF triples.

159 TRIPLES      21 PREDICATES      127 URIs      119 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s41971-018-0034-x schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Nf9820e435cf7474f9bf2e4b5ba354926
4 schema:datePublished 2018-08
5 schema:datePublishedReg 2018-08-01
6 schema:description The European Association for the Study of the Liver (EASL) has presented updated recommendations for the treatment of acute and chronic hepatitis C. From this, the recommendations relevant for Austrian and European practice have been extracted, taking into account current developments in the diagnostic workup including the necessary screening measures, treatment indications and therapeutic measures to be initiated as well as the contraindications to be observed. The use of various fixed combinations for different genotypes depending on liver pathology is comprehensively presented. The specific situations of substance abuse or relevant concomitant medication, after liver transplantation, in the case of hepatitis C virus (HCV) recurrent disease and in the presence of immune complex deposits are also discussed. In the case of HCV-positive organ recipients and donors and in the case of renal insufficiency or other relevant comorbidities, anti-HCV therapy must be adapted accordingly. Separate monitoring of therapy might be necessary. Treatment of children and adolescents should be tailored to the specific needs of the age group concerned. However, pangenotypical regimes have not yet been approved for children under 12 years of age. The indication of the various effective substances in primary therapy and after possible therapy failure must be made individually and take into consideration the individual disease constellations. Where appropriate, resistance testing can be of help. After successful treatment, individually adapted aftercare should be provided in order to recognize possible progression of liver disease or reinfections at an early stage.
7 schema:genre article
8 schema:inLanguage en
9 schema:isAccessibleForFree false
10 schema:isPartOf N0711500fd26542459aac2da748a9530b
11 Nda7f1062eb104ddca5b483eae8943043
12 sg:journal.1035274
13 schema:keywords Behandlung
14 C virus (HCV) recurrent disease
15 C.
16 Empfehlungen der Europäischen Lebergesellschaft (EASL) zur Behandlung
17 European Association
18 European practice
19 Europäischen Lebergesellschaft (EASL) zur Behandlung
20 HCV-positive organ recipients
21 Lebergesellschaft (EASL) zur Behandlung
22 abuse
23 account current developments
24 adolescents
25 aftercare
26 age
27 age groups
28 anti-HCV therapy
29 association
30 cases
31 children
32 chronic hepatitis C.
33 combination
34 comorbidities
35 complex deposits
36 concomitant medications
37 consideration
38 constellation
39 contraindications
40 current developments
41 deposits
42 der Europäischen Lebergesellschaft (EASL) zur Behandlung
43 development
44 diagnostic workup
45 different genotypes
46 disease
47 disease constellation
48 donors
49 early stages
50 effective substances
51 failure
52 genotypes
53 group
54 help
55 hepatitis C
56 hepatitis C virus (HCV) recurrent disease
57 hepatitis C.
58 immune complex deposits
59 indications
60 individual disease constellations
61 insufficiency
62 liver
63 liver disease
64 liver pathology
65 liver transplantation
66 measures
67 medications
68 monitoring
69 necessary screening measures
70 need
71 order
72 organ recipients
73 pangenotypical regimes
74 pathology
75 possible progression
76 possible therapy failure
77 practice
78 presence
79 primary therapy
80 progression
81 recipients
82 recommendations
83 recurrent disease
84 regime
85 reinfection
86 relevant comorbidities
87 relevant concomitant medication
88 renal insufficiency
89 resistance testing
90 screening measure
91 separate monitoring
92 situation
93 specific needs
94 specific situations
95 stage
96 study
97 substance abuse
98 substances
99 successful treatment
100 testing
101 therapeutic measures
102 therapy
103 therapy failure
104 transplantation
105 treatment
106 treatment indications
107 treatment of children
108 use
109 virus (HCV) recurrent disease
110 workup
111 years
112 years of age
113 zur Behandlung
114 schema:name Die Empfehlungen der Europäischen Lebergesellschaft (EASL) zur Behandlung der Hepatitis C (Version 2018)
115 schema:pagination 87-96
116 schema:productId N67c678f211294eacaf01d772e10153b8
117 Nb6b131d9231940968f3104122478b7f7
118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106967551
119 https://doi.org/10.1007/s41971-018-0034-x
120 schema:sdDatePublished 2021-11-01T18:31
121 schema:sdLicense https://scigraph.springernature.com/explorer/license/
122 schema:sdPublisher Ncf27c1f385174399b22471253fc5aa4a
123 schema:url https://doi.org/10.1007/s41971-018-0034-x
124 sgo:license sg:explorer/license/
125 sgo:sdDataset articles
126 rdf:type schema:ScholarlyArticle
127 N0711500fd26542459aac2da748a9530b schema:issueNumber 3
128 rdf:type schema:PublicationIssue
129 N67c678f211294eacaf01d772e10153b8 schema:name doi
130 schema:value 10.1007/s41971-018-0034-x
131 rdf:type schema:PropertyValue
132 Nb6b131d9231940968f3104122478b7f7 schema:name dimensions_id
133 schema:value pub.1106967551
134 rdf:type schema:PropertyValue
135 Ncf27c1f385174399b22471253fc5aa4a schema:name Springer Nature - SN SciGraph project
136 rdf:type schema:Organization
137 Nda7f1062eb104ddca5b483eae8943043 schema:volumeNumber 16
138 rdf:type schema:PublicationVolume
139 Nf9820e435cf7474f9bf2e4b5ba354926 rdf:first sg:person.01046032607.37
140 rdf:rest rdf:nil
141 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
142 schema:name Medical and Health Sciences
143 rdf:type schema:DefinedTerm
144 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
145 schema:name Clinical Sciences
146 rdf:type schema:DefinedTerm
147 sg:journal.1035274 schema:issn 1728-6263
148 1728-6271
149 schema:name Journal für Gastroenterologische und Hepatologische Erkrankungen
150 schema:publisher Springer Nature
151 rdf:type schema:Periodical
152 sg:person.01046032607.37 schema:affiliation grid-institutes:grid.415431.6
153 schema:familyName Peck-Radosavljevic
154 schema:givenName Markus
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046032607.37
156 rdf:type schema:Person
157 grid-institutes:grid.415431.6 schema:alternateName Abteilung Gastroenterologie und Hepatologie, Endokrinologie, Rheumatologie und Nephrologie, Klinikum Klagenfurt am Wörthersee, Feschnigstraße 11, 9020, Klagenfurt, Österreich
158 schema:name Abteilung Gastroenterologie und Hepatologie, Endokrinologie, Rheumatologie und Nephrologie, Klinikum Klagenfurt am Wörthersee, Feschnigstraße 11, 9020, Klagenfurt, Österreich
159 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...